Alyssa L. Perez

Associate

纽约 + 1.212.326.3609

联系：

Share

Alyssa Perez advises public and private companies and private equity firms on mergers and acquisitions, divestitures, and other strategic transactions in a range of industries, including consumer products, manufacturing, health care, software, and technology. Alyssa also has experience advising companies on corporate governance matters and shareholder engagement.

Alyssa's recent experience includes advising The Procter & Gamble Company in its $3.8 billion acquisition of Thorne and West Pharmaceutical Services in its $112.5 million sale to AbbVie.

Alyssa was also a member of the teams that advised Boviet Solar Technology in its sale to INOX Solar Americas ($750 million); VSE Corporation in its acquisition of Aero 3, a diversified global MRO (maintenance, repair, and overhaul) service provider ($350 million); and Kraken in its acquisition of NinjaTrader ($1.5 billion).

经验

  • The Procter & Gamble Company acquires Thorne from L Catterton for $3.8 billionJones Day is advising The Procter and Gamble Company (NYSE: PG) in the $3.8 billion acquisition of Thorne, a leader in science-backed health and wellness solutions, from L Catterton.
  • Boviet Solar Technology sells U.S. PV module manufacturing and PV cell manufacturing assets to INOX Solar Americas for approximately $750 millionJones Day advised Boviet Solar USA Ltd, a leading solar technology company specializing in manufacturing top-performing Gamma Series™ Monofacial and Vega Series™ Bifacial PV modules, in the sale of its U.S.-based subsidiaries', Boviet Solar Technology (North Carolina) LLC, and Boviet Solar Cell Technology (North Carolina) LLC, assets to INOX Solar Americas, LLC, a U.S.-based renewable energy company backed by INOX Clean Energy Limited, for approximately $750 million.
  • Aurelius finances acquisition of Sensus InternationalJones Day advised private equity investor Aurelius on the financing of its acquisition of Sensus International, the international water and heat metering business of US-based Xylem Inc.
  • West Pharmaceutical Services sells manufacturing and supply rights for SmartDose® 3.5mL On-Body Delivery System to AbbVieJones Day is advising West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, in the sale of all manufacturing and supply rights for SmartDose® 3.5mL On-Body Delivery System and associated facilities to AbbVie (NYSE: ABBV) for $112.5 million at close, subject to working capital and other adjustments.
  • VSE acquires Aero 3Jones Day advised VSE Corporation in the $350 million acquisition of GenNx/AeroRepair IntermediateCo Inc., the parent company of Aero 3, Inc., a portfolio company of GenNx360 Capital Partners and a diversified global Maintenance, Repair and Overhaul (MRO) service provider and distributor supporting the commercial wheel and brake aftermarket.
  • Verint agrees to be acquired by Thoma Bravo for $2 billionJones Day advised Verint Systems Inc. (NASDAQ: VRNT), a global leader in Customer Experience (CX) Automation software, in connection with a take private transaction entered into with Thoma Bravo, a leading private equity firm primarily investing in software and technology companies, to become a privately held company in an all-cash transaction reflecting an enterprise value of $2 billion.
  • Kraken acquires NinjaTraderJones Day advised Payward, Inc. d/b/a Kraken, a cryptocurrency exchange, in connection with its $1.5 billion acquisition of NinjaTrader Group Holdings, LLC, a leading futures trading broker.
  • Wells Fargo provides $500 million revolving loan secured by 65 industrial propertiesJones Day represented Wells Fargo Bank, National Association, as administrative agent, in connection with a $500 million revolving loan secured by a portfolio of 65 industrial properties across Georgia, Illinois, Minnesota, North Carolina, Texas, and Utah.
    •

    发送前请注意

    *Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice